Skip to main content
SpringerLink
Log in

Delavirdine

Clinical Pharmacokinetics and Drug Interactions

  • Review Article
  • Drug Disposition
  • Published:
Clinical Pharmacokinetics Aims and scope Submit manuscript

Abstract

Delavirdine, a non-nucleoside reverse transcriptase inhibitor (NNRTI), is a potent and specific inhibitor of HIV-1 reverse transcriptase. The approved therapeutic regimen for delavirdine is 400mg 3 times daily in combination with appropriate antiretroviral agents; however, a dose of 600mg twice daily appears to provide similar systemic exposure. The steady-state pharmacokinetics of delavirdine are not appreciably affected by food.

Delavirdine undergoes extensive metabolism by cytochrome P450 (CYP) with little urinary excretion of unchanged drug. Metabolic drug interactions between delavirdine and nucleoside reverse transcriptase inhibitors are unlikely as their metabolic pathways differ; delavirdine has no effect on the pharmacokinetics of zidovudine. Concomitant use of CYP inducers, such as rifampicin (rifampin), rifabutin, phenytoin, phenobarbital or carbamazepine, should be avoided since delavirdine plasma concentrations are significantly lowered. Reduction in gastric acidity (pH > 3) decreases the extent of delavirdine absorption, so administration of antacids and the buffered formulations of didanosine should be separated from that of delavirdine by at least 1 hour.

Delavirdine, unlike other currently available NNRTI agents, is an inhibitor rather than an inducer of CYP isozymes. Consequently, the drug interaction profile and rationale for combining delavirdine with other antiretroviral agents is unique among the current NNRTI agents. Delavirdine inhibits the CYP3A4-mediated metabolism of HIV protease inhibitors and thereby increases systemic exposure to protease inhibitors. The ability of delavirdine to enhance the pharmaco-kinetic profiles of protease inhibitors may permit the use of simplified administration regimens. Combining delavirdine and indinavir removes the food restrictions during indinavir administration. Furthermore, the superior virological response observed in antiretroviral regimens containing delavirdine and protease inhibitors has been attributed to the favourable pharmacokinetic interactions and the introduction of a new drug class in NNRTI-naïve therapy-experienced patients.

Pharmacokinetic drug interactions are an important consideration in selecting an HIV treatment regimen, due to the multiplicity of drugs that are coadministered and the varying direction and magnitude of interaction that can occur. Considerations for utilising delavirdine in a treatment regimen are different than for other NNRTI agents due to the unique drug interaction profile of delavirdine.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Fig. 1
Table II
Table III
Table IV
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. De Clercq E. The role of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection. Antiviral Res 1998; 38: 153–79

    Article  PubMed  Google Scholar 

  2. Bellman PC. Clinical experience with adding delavirdine to combination therapy in patients in whom multiple antiretroviral treatment including protease inhibitors has failed. AIDS 1998; 12: 1333–40

    Article  PubMed  CAS  Google Scholar 

  3. Friedland GH, Pollard R, Griffith B, et al. Efficacy and safety of delavirdine mesylate with zidovudine and didanosine compared with two-drug combinations of these agents in persons with HIV disease with CD4 counts of 100 to 500 cells/mm3 (ACTG 261). ACTG 261 Team. J Acquir Immune Defic Syndr 1999; 21: 281–92

    Article  PubMed  CAS  Google Scholar 

  4. Green S, Para MF, Daly PW, et al. Interim analysis of plasma viral burden reductions and CD4 increases in HIV-1 infected patients with Rescriptor (DLV) + Retrovir (ZDF) + Epivir (3TC) [abstract no. 12219]. 12th World AIDS Conference; 1998 Jun 28–Jul 3; Geneva, Switzerland

    Google Scholar 

  5. Gulick RM, Hu XJ, Fiscus SA, et al. Randomized study of saquinavir with ritonavir or nelfinavir together with delavirdine, adefovir, or both in human immunodeficiency virusinfected adults with virologic failure on indinavir: AIDS clinical trials group study 359. J Infect Dis 2000; 182: 1375–84

    Article  PubMed  CAS  Google Scholar 

  6. Kuritzkes DR, Bassett RL, Johnson VA, et al. Continued lamivudine versus delavirdine in combination with indinavir and zidovudine or stavudine in lamivudine-experienced patients: results of Adult AIDS Clinical Trials Group protocol 370. AIDS 2000; 14: 1553–61

    Article  PubMed  CAS  Google Scholar 

  7. Conway B. Initial therapy with protease inhibitor-sparing regimens: evaluation of nevirapine and delavirdine. Clin Infect Dis 2000; 30 Suppl. 2: S130–4

    Article  PubMed  CAS  Google Scholar 

  8. Para M, Conway B, Green S, et al. Safety and efficacy of delavirdine (DLV) in combination with zidovudine (ZDV) and lamivudine (3TC): final 52-week analysis [abstract no. 1979]. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1999 Sep 26–29; San Francisco

    Google Scholar 

  9. Para M, Beal J, Rathbun C, et al. Potent activity with lower doses of indinavir (IDV), using delavirdine (DLV) in combination with zidovudine (ZDV): 48 week analysis [abstract no. 1985]. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1999 Sep 26–29; San Francisco

    Google Scholar 

  10. Adkins JC, Noble S. Efavirenz. Drugs 1998; 56: 1055–64

    Article  PubMed  CAS  Google Scholar 

  11. Lamson M, MacGregor T, Riska P, et al. Nevirapine induces both CYP3A4 and CYP2B6 metabolic pathways. Clin Pharmacol Ther 1999; 65: 137

    Article  Google Scholar 

  12. Erickson DA, Mather G, Trager WF, et al. Characterization of the in vitro biotransformation of the HIV-1 reverse transcriptase inhibitor nevirapine by human hepatic cytochromes P-450. Drug Metab Dispos 1999; 27: 1488–95

    PubMed  CAS  Google Scholar 

  13. Reliquet V, Peytavin G, Allavena C, et al. The pharmacokinetics (PK) and tolerance of once daily nevirapine (NVP) and twice daily emivirine(EMV) when used in combination [abstract no. 1633]. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2000 Sep 17–20; Toronto

    Google Scholar 

  14. Rescriptor® package insert. San Diego (CA): Agouron Pharmaceuticals Inc., 1999

  15. Sustiva™ package insert. Wilmington (DE): DuPont Pharmaceuticals Corporation, 2000

  16. Viramune® package insert. Ridgefield (CT): Boehringer Ingelheim Pharmaceuticals Inc., 1998

  17. Cox SR, Della-Coletta AA, Turner SW, et al. Single-dose pharmacokinetic (PK) studies with delavirdine (DLV) mesylate: dose proportionality and effects of food and antacid [abstract no. A54]. 34th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1994 Oct 4–7; Orlando

    Google Scholar 

  18. Morse GD, Fischl MA, Cox SR, et al. Effect of food on the steady-state (SS) pharmacokinetics of delavirdine mesylate (DLV) in HTV + patients [abstract no. 130]. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1995 Sep 17–20; San Francisco

    Google Scholar 

  19. Freimuth WW Delavirdine mesylate, a potent non-nucleoside HIV-1 reverse transcriptase inhibitor. Adv Exp Med Biol 1996; 394: 279–89

    PubMed  CAS  Google Scholar 

  20. Shelton M, Adams J, Hewitt R, et al. Reduced delavirdine (DLV) exposure in HTV+ subjects with gastric hypoacidity (GH) [abstract no. A31]. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1995 Sep 17–20; San Francisco

    Google Scholar 

  21. Khalileh SG, Forrest A, Shelton M, et al. Population PKs of delavirdine (DLV) and N-desalkyl delavirdine (N-DLV) [abstract no. A-7]. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1997 Sep 28–Oct 1; Toronto

    Google Scholar 

  22. Smith PF, Dicenzo R, Forrest A, et al. Population pharmacokinetics (PK) of delavirdine (DLV) and N-DLV [abstract no. 1666]. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2000 Sep 17–20; Toronto

    Google Scholar 

  23. Chaput AJ, D’Ambrosio R, Morse GD. In vitro protein-binding characteristics of delavirdine and its N-dealkylated metabolite. Antiviral Res 1996; 32: 81–9

    Article  PubMed  CAS  Google Scholar 

  24. Cheng CL, Smith DE, Carver PL, et al. Steady-state pharmacokinetics of delavirdine in HIV-positive patients: effect on erythromycin breath test. Clin Pharmacol Ther 1997; 61: 531–43

    Article  PubMed  CAS  Google Scholar 

  25. Davey Jr RT, Chaitt DG, Reed GF, et al. Randomized, controlled phase I/II, trial of combination therapy with delavirdine (U-90152S) and conventional nucleosides in human immunodeficiency virus type 1-infected patients. Antimicrob Agents Chemother 1996; 40: 1657–64

    PubMed  CAS  Google Scholar 

  26. Voorman RL, Payne NA, Wienkers LC, et al. Interaction of delavirdine with human liver microsomal cytochrome P450: inhibition of CYP2C9, CYP2C19, and CYP2D6. Drug Metab Dispos 2001; 29: 41–7

    PubMed  CAS  Google Scholar 

  27. Voorman RL, Maio SM, Hauer MJ, et al. Metabolism of delavirdine, a human immunodeficiency virus type-1 reverse transcriptase inhibitor, by microsomal cytochrome P450 in humans, rats, and other species: probable involvement of CYP2D6 and CYP3A. Drug Metab Dispos 1998; 26: 631–9

    PubMed  CAS  Google Scholar 

  28. Voorman RL, Maio SM, Payne NA, et al. Microsomal metabolism of delavirdine: evidence for mechanism-based inactivation of human cytochrome P450 3A. J Pharmacol Exp Ther 1998;287:381–8

    PubMed  CAS  Google Scholar 

  29. Data on file, Agouron Pharmaceuticals, Inc., 1999

  30. Cox SR, Phillips L. Simulations with a population pharmacokinetic (PPK) model for delavirdine (DLV) predict the same systemic steady-state (SS) exposure for 600mg BID and 400mg TID regimens [abstract no 462]. 36th Annual Meeting of the Infectious Disease Society of America; 1998 Nov 12–15; Denver

    Google Scholar 

  31. Ferry JJ, Schneck DW, Carlson GF, et al. Evaluation of the pharmacokinetic (PK) interaction between ritonavir (R) and delavirdine (DLV) in healthy volunteers [abstract no. 385]. 4th Conference n Retroviruses and Opportunistic Infections; 1997 Jan 22–26; Washington, DC

    Google Scholar 

  32. Tran JQ, Petersen C, Garrett M, et al. Delavirdine significantly increases plasma concentrations of amprenavir in healthy volunteers. AIDS 2000; 14 Suppl. 4: S92

    Google Scholar 

  33. Cox S, Conway B, Freimuth W, et al. Pilot study of BID and TID combinations of saquinavir-SGC (S), delavirdine (D), zidovudine (ZDV) and lamivudine (3TC) as initial therapy: pharmacokinetic (PK) interaction between S-SGC and D [abstract no. 82]. 7th Conference on Retroviruses and Opportunistic Infections; 2000 Jan 3–Feb 2; San Francisco

    Google Scholar 

  34. Borin MT, Cox SR, Herman BD, et al. Effect of fluconazole on the steady-state pharmacokinetics of delavirdine in human immunodeficiency virus-positive patients. Antimicrob Agents Chemother 1997; 41: 1892–7

    PubMed  CAS  Google Scholar 

  35. Miners JO, Birkett DJ. Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. Br J Clin Pharmacol 1998; 45: 525–38

    Article  PubMed  CAS  Google Scholar 

  36. Blanco JL, Mallolas J, Sarasa M, et al. A pilot study of a twice-daily (BID) combination of indinavir/delavirdine plus two nucloside analogues for salvage therapy in HTV-1 infected patients [abstract no. 1543]. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2000 Sep 17–20; Toronto

    Google Scholar 

  37. Conway B, Chu A, Tran J, et al. Apilot study of combinations of delavirdine (DLV), zidovudine (ZDV), lamivudine (3TC) & saquinavir-SGC (Fortovase, FTV) as initial antiretroviral therapy: Virologic and pharmacokinetic considerations [abstract no. 331]. 8th Conference on Retroviruses and Opportunistic Infections; 2001 Feb 4–8; Chicago

    Google Scholar 

  38. Demeter LM, Shafer RW, Meehan PM, et al. Delavirdine susceptibilities and associated reverse transcriptase mutations in human immunodeficiency virus type 1 isolates from patients in a phase I/II trial of delavirdine monotherapy (ACTG 260). Antimicrob Agents Chemother 2000; 44: 794–7

    Article  PubMed  CAS  Google Scholar 

  39. Chong KT, Pagano PJ, Hinshaw RR. Synergistic inhibition of HIV replication in vitro by U-90152 (BHAP) and protease inhibitor, U-75875 [abstract no. 0557]. 9th International Conference on AIDS; 1993 Jun 6–11; Berlin

    Google Scholar 

  40. Chong KT, Pagano PJ, Hinshaw RR. Bisheteroarylpiperazine reverse transcriptase inhibitor in combination with 3′-azido-3′-deoxythymidine or 2′,3′-dideoxycytidine synergistically inhibits human immunodeficiency virus type 1 replication in vitro. Antimicrob Agents Chemother 1994; 38: 288–93

    Article  PubMed  CAS  Google Scholar 

  41. Chong KT, Pagano PJ. Antiviral effect of convergent vs. divergent drug combination on HIV-1 spread in vitro [abstract no. PA0314]. 10th International Conference on AIDS; 1994 Aug 7–12; Yokohama

    Google Scholar 

  42. Chong KT, Pagano PJ. Synergistic inhibition of human immunodeficiency type 1 replication in vitro by two and three-drug combination of delavirdine, lamivudine and zidovudine [abstract no. 1103]. XI International Conference on AIDS; 1996 Jul 7–12; Vancouver

    Google Scholar 

  43. Para M, Conway B, Kurtizkes D, et al. Treatment with delavirdine in combination with NRTIs and/or PIs is not associated with lipodistrophy or metabolic lipid/glucose disturbances. Antiviral Therapy 1999; 4 Suppl. 2: 70

    Google Scholar 

  44. Roberts AD, Liappis A, Chinn CD, et al. Effect of delavirdine on plasma lipids and lipoproteins in patients receiving antiretroviral therapy [abstract no. 351]. 38th Annual Meeting of the Infectious Diseases Society of America; 2000 Sep 7–10; New Orleans

    Google Scholar 

  45. Cox SR, Borin MT, Driver MR, et al. Effect of Clarithromycin (CLAR) on the steady-state pharmacokinetics (PK) of delavirdine (DLV) in HTV-1 patients [abstract no. 487]. 2nd National Conference on Human Retroviruses and Related Infections; 1995 Jan 29–Feb 2; Washington, DC

    Google Scholar 

  46. Venkatakrishnan K, von Moltke LL, Greenblatt DJ. Effects of the antifungal agents on oxidative drug metabolism: clinical relevance. Clin Pharmacokinet 2000; 38: 111–80

    Article  PubMed  CAS  Google Scholar 

  47. Borin MT, Chambers JH, Carel BJ, et al. Pharmacokinetic study of the interaction between rifabutin and delavirdine mesylate in HIV-1 infected patients. Antiviral Res 1997; 35: 53–63

    Article  PubMed  CAS  Google Scholar 

  48. Borin MT, Chambers JH, Carel BJ, et al. Pharmacokinetic study of the interaction between rifampin and delavirdine mesylate. Clin Pharmacol Ther 1997; 61: 544–53

    Article  PubMed  CAS  Google Scholar 

  49. Panel on clinical practices for treatment of HIV infection, Department of Health and Human Services, Henry J. Kaiser Family Foundation. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Available from URL: http://www.hivatis.org [Accessed on 2001 Mar 5]

  50. Morse GD, Cox SR, DeRemer MF, et al. Zidovudine (ZDF) pharmacokinetics (PK) during an escalating, multiple-dose study of delavirdine (DLV) mesylate [abstract no 156]. 34th International Conference on Antimicrobial Agents and Chemotherapy; 1994 Oct 4–7; Orlando

    Google Scholar 

  51. Acosta EP, Page LM, Fletcher CV. Clinical pharmacokinetics of zidovudine: an update. Clin Pharmacokinet 1996; 30: 251–62

    Article  PubMed  CAS  Google Scholar 

  52. Morse GD, Fischl MA, Shelton MJ, et al. Single-dose pharmacokinetics of delavirdine mesylate and didanosine in patients with human immunodeficiency virus infection. Antimicrob Agents Chemother 1997; 41: 169–74

    PubMed  CAS  Google Scholar 

  53. Cox SR, Cohn SE, Greisberger C, et al. Evaluation of the steady-state (SS) phannacokinetic interaction between didanosine (ddI) and delavirdine mesylate (DLV) in HIV + patients [abstract no. 131]. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1995 Sep 17–20; San Francisco

    Google Scholar 

  54. Mummaneni V, Damle B, Kaul S, et al. Lack of effect of didanosine encapsulated enteric coated beadlet formulation on the pharmacokinetics of indinavir, ketoconazole, and Ciprofloxacin in healthy volunteers [abstract no. 1629]. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2000 Sep 17–20; Toronto

    Google Scholar 

  55. von Moltke LL, Greenblatt DJ, Grassi JM, et al. Protease inhibitors as inhibitors of human cytochromes P450: high risk associated with ritonavir. J Clin Pharmacol 1998; 38: 106–11

    Google Scholar 

  56. Eagling VA, Back DJ, Barry MG. Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir. Br J Clin Pharmacol 1997;44: 190–4

    Article  PubMed  CAS  Google Scholar 

  57. Tseng AL. Compliance issues in the treatment of HIV infection. Am J Health Syst Pharm 1998; 55: 1817–24

    PubMed  CAS  Google Scholar 

  58. Paris D, Ledergerber B, Weber R, et al. Incidence and predictors of virologic failure of antiretroviral triple-drug therapy in a community-based cohort. AIDS Res Hum Retroviruses 1999; 15: 1631–8

    Article  PubMed  CAS  Google Scholar 

  59. Gifford AL, Bormann JE, Shively MJ, et al. Predictors of self-reported adherence and plasma HIV concentrations in patients on multidrug antiretroviral regimens. J Acquir Immune Defic Syndr 2000; 23: 386–95

    PubMed  CAS  Google Scholar 

  60. Bertz R, Lam W, Hsu A, et al. Assessment of the pharmacokinetic interaction between ABT-378/ritonavir (ABT-378/r) and efavirenz (EFV) in healthy volunteers and in HIV + subjects [abstract no. 424]. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2000 Sep 17–20; Toronto

    Google Scholar 

  61. Morse GD, Shelton MJ, Hewitt RG, et al. Ritonavir (RIT) pharmacokinetics (PK) during combination therapy with delavirdine (DLV) [abstract no. 343]. 5th Conference on Retroviruses and Opportunistic Infections; 1998 Feb 1–5; Chicago

    Google Scholar 

  62. Murphy RL, Sommadossi JP, Lamson M, et al. Antiviral effect and pharmacokinetic interaction between nevirapine and indinavir in persons infected with human immunodeficiency virus type 1. J Infect Dis 1999; 179: 1116–23

    Article  PubMed  CAS  Google Scholar 

  63. Falloon J, Piscitelli S, Vogel S, et al. Combination therapy with amprenavir, abacavir, and efavirenz in human immunodeficiency virus (HIV)-infected patients failing a protease-inhibitor regimen: pharmacokinetic drug interactions and antiviral activity. Clin Infect Dis 2000; 30: 313–8

    Article  PubMed  CAS  Google Scholar 

  64. Fiske WD, Benedek LH, White SJ, et al. Pharmacokinetic interaction between efavirenz (EFV) and nelfinavir mesylate (NFV) in healthy volunteers [abstract no. 349]. 5th Conference on Retroviruses and Opportunistic Infections; 1998 Feb 1–5; Chicago

    Google Scholar 

  65. Sahai J, Cameron W, Salgo M, et al. Drug interaction study between saquinavir (SQV) and nevirapine (NVP) [abstract no. 496]. 4th International Conference on Retroviruses and Opportunistic Infections; 1997 Jan 22–26; Washington, DC

    Google Scholar 

  66. Shelton MJ, Hewitt RG, Adams JM, et al. Delavirdine (DLV) mesylate pharmacokinetics (PK) during combination therapy with ritonavir (RIT) [abstract no. A63]. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1997 Sep 28–Oct 1; Toronto

    Google Scholar 

  67. Skowron G, Leoung G, Kerr B, et al. Lack of phannacokinetic interaction between nelfinavir and nevirapine. AIDS 1998; 12: 1243–4

    Article  PubMed  CAS  Google Scholar 

  68. Tran JQ, Petersen C, Garrett MK, et al. The pharmacokinetics (PK) and tolerability of indinavir (IDV) and delavirdine (DLV) administered twice-daily (BID) in the absence and presence of food in healthy volunteers [abstract no. 1634]. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2000 Sep 17–20; Toronto

    Google Scholar 

  69. Tran JQ, Petersen C, Garrett M, et al. Pharmacokinetics of indinavir/delavirdine 1200/600mg twice daily with and without food. AIDS 2000; 14 Suppl. 4: S92

    Google Scholar 

  70. Kaletra™ package insert. North Chicago (IL): Abbott Laboratories Inc, 2000

  71. Plosker GL, Noble S. Indinavir: a review of its use in the management of HIV infection. Drugs 1999; 58: 1165–203

    Article  PubMed  CAS  Google Scholar 

  72. Burger DM, Hoetelmans RM, Hugen PW, et al. Low plasma concentrations of indinavir are related to virological treatment failure in HIV-1 -infected patients on indinavir-containing triple therapy. Antiviral Ther 1998; 3: 215–20

    CAS  Google Scholar 

  73. Acosta EP, Henry K, Baken L, et al. Indinavir concentrations and antiviral effect. Pharmacotherapy 1999; 19: 708–12

    Article  PubMed  CAS  Google Scholar 

  74. Dieleman JP, Gyssens IC, van der Ende ME, et al. Urological complaints in relation to indinavir plasma concentrations in HTV-infected patients. AIDS 1999; 13: 473–8

    Article  PubMed  CAS  Google Scholar 

  75. Ferry JJ, Herman BD, Carel BJ, et al. Pharmacokinetic drugdrug interaction study of delavirdine and indinavir in healthy volunteers. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 18: 252–9

    Article  PubMed  CAS  Google Scholar 

  76. Decker CJ, Laitinen LM, Bridson GW, et al. Metabolism of amprenavir in liver microsomes: role of CYP3A4 inhibition for drug interactions. J Pharm Sci 1998; 87: 803–7

    Article  PubMed  CAS  Google Scholar 

  77. Woolley J, Studenberg S, Boehlert C, et al. Cytochrome P-450 isozyme induction, inhibition, and metabolism studies with the HIV protease inhibitor, 141W94 [abstract no. A60]. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1997 Sep 28–Oct 1; Toronto

    Google Scholar 

  78. Polk RE, Crouch MA, Israel DS, et al. Phannacokinetic interaction between ketoconazole and amprenavir after single doses in healthy men. Pharmacotherapy 1999; 19: 1378–84

    Article  PubMed  CAS  Google Scholar 

  79. Sadler BM, Piliero PJ, Preston SL, et al. Pharmacokinetic (PK) drug-interaction between amprenavir (APV) and ritonavir (RTV) in HIV-seronegative subjects after multiple, oral dosing [abstract no 77]. 7th Conference on Retroviruses and Opportunistic Infections; 2000 Jan 30–Feb 2; San Francisco

    Google Scholar 

  80. Sadler BM, Hanson CD, Chittick GE, et al. Safety and phannacokinetics of amprenavir (141W94), a human immunodeficiency virus (HIV) type 1 protease inhibitor, following oral administration of single doses to HIV-infected adults. Antimicrob Agents Chemother 1999; 43: 1686–92

    PubMed  CAS  Google Scholar 

  81. Wintergerst U, Engelhorn C, Kurowski M, et al. Pharmacokinetic interaction of amprenavir in combination with efavirenz or delavirdine in HIV-infected children. AIDS 2000; 14: 1866–8

    Article  PubMed  CAS  Google Scholar 

  82. Vella S, Floridia M. Saquinavir: clinical phannacology and efficacy. Clin Pharmacokinet 1998; 34: 189–201

    Article  PubMed  CAS  Google Scholar 

  83. Cox SR, Batts DH, Stewart F, et al. Evaluation of the pharmacokinetic (PK) interaction between saquinavir (SQV) and delavirdine (DLV) in healthy volunteers [abstract no. 381]. 4th Conference on Retroviruses and Opportunistic Infections; 1997 Jan 22–26; Washington, DC

    Google Scholar 

  84. Lillibridge JH, Liang BH, Kerr BM, et al. Characterization of the selectivity and mechanism of human cytochrome P450 inhibition by the human immunodeficiency virus-protease inhibitor nelfinavir mesylate. Drug Metab Dispos 1998; 26: 609–16

    PubMed  CAS  Google Scholar 

  85. Lillibridge JH, Lee CA, Pithavala YK, et al. The role of polymorphic CYP2C19 in the metabolism of nelfinavir mesylate [abstractno. 1156]. 5th International ISSX Meeting; 1998 Oct 22–25; Cairns

    Google Scholar 

  86. Cox SR, Schneck DW, Herman BD, et al. Delavirdine (DLV) and nelfinavir (NFV): a pharmacokinetic (PK) drug-drug interaction study in healthy adult volunteers [abstract no. 345]. 5th Conference on Retroviruses and Opportunistic Infections; 1998 Feb 1–5; Chicago

    Google Scholar 

  87. Slater L, Goodgame J, Wathen L, et al. Antiviral effect of increasing nelfinavir (NFV) concentrations using delavirdine (DLV) in combination with didanosine (ddI) and stavudine (d4T) is maintained through 48 weeks of therapy [abstract no. 1989]. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1999 Sep 26–29); San Francisco

    Google Scholar 

  88. Hsu A, Granneman GR, Bertz RJ. Ritonavir: clinical pharmacokinetics and interactions with other anti-HTV agents. Clin Pharmacokinet 1998; 35: 275–91

    Article  PubMed  CAS  Google Scholar 

  89. Greenblatt DJ, von Moltke LL, Harmatz JS, et al. Alprazolamritonavir interaction: implications for product labeling. Clin Pharmacol Ther 2000; 67: 335–41

    Article  PubMed  CAS  Google Scholar 

  90. Kumar GN, Dykstra J, Roberts EM, et al. Potent inhibition of the cytochrome P-450 3A-mediated human liver microsomal metabolism of a novel HIV protease inhibitor by ritonavir: a positive drug-drug interaction. Drug Metab Dispos 1999; 27: 902–8

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Agouron Pharmaceuticals, Inc., A Pfizer Company, La Jolla, California, USA

    Jonathan Q. Tran & Bradley M. Kerr

  2. Departments of Medicine and Pharmacology, University of Colorado Health Sciences Center, Denver, Colorado, USA

    John G. Gerber

Authors
  1. Jonathan Q. Tran
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. John G. Gerber
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Bradley M. Kerr
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jonathan Q. Tran.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Tran, J.Q., Gerber, J.G. & Kerr, B.M. Delavirdine. Clin Pharmacokinet 40, 207–226 (2001). https://doi.org/10.2165/00003088-200140030-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003088-200140030-00005

Keywords

Search

Navigation